Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02250326
Title Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
Acronym abound2L+
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene Corporation
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | GBR | FRA | ESP | DEU | CAN


No variant requirements are available.